PMC 8716657
Visit our website and click on " Book an Appointment ." Select your preferred date, time, and location
Absolute Contraindications BPC-157 is not recommended for patients with: Active cancer (any type) theoretical concern regarding angiogenesis promotion Pregnancy or breastfeeding insufficient safety data Known hypersensitivity to any component of the formulation Relative Contraindications (Require Individualized Assessment) History of cancer after completion of treatment, a waiting period and oncology clearance may be appropriate Autoimmune disease especially if active or requiring immunosuppressive therapy Anticoagulant use injection site bleeding risk, though minimal with proper technique Severe renal or hepatic impairment dosing adjustments may be needed Monitoring and Follow-Up Patients on BPC-157 protocols are monitored through: Baseline and follow-up labs including inflammatory markers (CRP, ESR), complete blood count, and metabolic panel Clinical assessments pain scores, range of motion, functional outcomes at 2-week, 4-week, and 8-week intervals Imaging when indicated repeat ultrasound or MRI for musculoskeletal conditions to document structural healing The Patient Journey: What to Expect For patients considering peptide therapy, understanding the timeline of response helps set realistic expectations
Standard dosing Daily dose: 300-600mcg per day Injection frequency: Once daily, preferably in the morning on an empty stomach Administration route: Subcutaneous injection Most users start at 300mcg to assess tolerance, then increase to 500-600mcg if the lower dose is well-tolerated but results are modest
Peptide therapy requires a prescription from a licensed provider
People often explore BPC-157 for: Athletes and active people in the Flathead Valley are often drawn to BPC-157 for its reputation in supporting faster recovery from the kind of wear and tear that comes with an active mountain lifestyle
